Eisler Capital (Us) LLC Cerevel Therapeutics Holdings, Inc. Transaction History
Eisler Capital (Us) LLC
- $5.6 Trillion
- Q2 2024
A detailed history of Eisler Capital (Us) LLC transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Eisler Capital (Us) LLC holds 20,331 shares of CERE stock, worth $0. This represents 0.01% of its overall portfolio holdings.
Number of Shares
20,331
Previous 16,899
20.31%
Holding current value
$0
Previous $714 Million
16.38%
% of portfolio
0.01%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding CERE
# of Institutions
217Shares Held
152MCall Options Held
2.19MPut Options Held
3M-
Bain Capital Investors LLC Boston, MA65.7MShares$065.37% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$012.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.54MShares$04.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.15MShares$00.01% of portfolio
-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...